Clinical Trials Browser

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT05789069 2025-11-21

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

83 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05768932 2025-10-15

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

260 enrolled

BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05632939 2025-09-10

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Phase 1/2 Active not recruiting

62 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed

291 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

65 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Phase 2 Recruiting

92 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT06914687 2025-04-06

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Clinical Trials

HERIZON-GEA-01

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

NeoTISLEGA

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

DisTinGuish

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

A Benefit Population Atlas of nICT Versus nCT for LAGC

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

TALENT

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma